Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mechanism Investigation of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma

NCT06652152 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06652152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06652152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mechanism Investigation of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma
Lead sponsor
Ruijin Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
October 30, 2024
Completion date
December 30, 2025
Enrollment
400 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma (dlbcl), double expressor lymphoma